Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 36.47 | -48.99 | -77.12 | |
| Graham Fair Price | 60.14 | 7.04 | 4.40 | |
| PEG | -66.33 | -0.34 | 1.02 | |
| Price/Book | -62.80 | 7.44 | 20.00 | |
| Price/Cash Flow | 8.37 | -76.77 | -83.79 | |
| Prices/Earnings | 28.93 | -15.25 | -21.46 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | 8.37 | -76.77 | -83.79 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 43.75 | -0.11 | -0.20 | |
| ROE | -0.23 | -0.12 | 47.66 | |
| ROIC | -0.23 | -0.13 | 43.36 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.55 | -0.33 | -65.43 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.21 | -0.57 | 167.64 | |
| EPS QOQ | 0.21 | -0.44 | 111.11 | |
| FCF QOQ | -0.27 | -0.27 | 0.07 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | < 0.005 | < 0.005 | -90.82 | |
| Quick Ratio | 6.74 | 13.18 | 95.61 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.92 | 4.25 | 121.36 | |
| Cash | 2.06 | 4.37 | 112.39 | |
| Capex | < 0.005 | < 0.005 | -298.08 | |
| Free Cash Flow | -0.46 | -0.41 | 10.14 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad